X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse AMAR REMEDIES with UNILEVER PLC. - UK - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AMAR REMEDIES vs UNILEVER PLC. (UK) - Comparison Results

UNILEVER PLC. (UK)
   Change

Unilever is an Anglo–Dutch multinational consumer goods company. It is present in 11 categories broadly divided into home care, personal care, refreshments and foods. Personal care and foods are the large segments with sales shares of 35% and 28%, re... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 AMAR REMEDIES   UNILEVER PLC.
EQUITY SHARE DATA
    AMAR REMEDIES
Jun-12
UNILEVER PLC.
Dec-14
AMAR REMEDIES/
UNILEVER PLC.
5-Yr Chart
Click to enlarge
High Rs1642,674-   
Low Rs862,168-   
Sales per share (Unadj.) Rs261.62,255.5-  
Earnings per share (Unadj.) Rs17.4256.8-  
Cash flow per share (Unadj.) Rs22.3309.3-  
Dividends per share (Unadj.) Rs089.43-  
Dividend yield (eoy) %03.7 0.0%  
Book value per share (Unadj.) Rs100.7635.7-  
Shares outstanding (eoy) m26.161,714.73-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.51.1 44.5%   
Avg P/E ratio x7.29.4 76.2%  
P/CF ratio (eoy) x5.67.8 71.7%  
Price / Book Value ratio x1.23.8 32.6%  
Dividend payout %034.8 0.0%   
Avg Mkt Cap Rs m3,2704,151,450 0.1%   
No. of employees `000NA173.0 0.0%   
Total wages/salary Rs m163483,412 0.0%   
Avg. sales/employee Rs ThNM22,356.2-  
Avg. wages/employee Rs ThNM2,794.3-  
Avg. net profit/employee Rs ThNM2,545.5-  
INCOME DATA
Net Sales Rs m6,8443,867,615 0.2%  
Other income Rs m2112,936 0.2%   
Total revenues Rs m6,8653,880,550 0.2%   
Gross profit Rs m1,131754,982 0.1%  
Depreciation Rs m12889,991 0.1%   
Interest Rs m39839,925 1.0%   
Profit before tax Rs m626638,002 0.1%   
Minority Interest Rs m0-27,468 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-500-   
Tax Rs m121170,160 0.1%   
Profit after tax Rs m455440,373 0.1%  
Gross profit margin %16.519.5 84.7%  
Effective tax rate %19.326.7 72.5%   
Net profit margin %6.611.4 58.4%  
BALANCE SHEET DATA
Current assets Rs m4,904985,908 0.5%   
Current liabilities Rs m3,5811,568,414 0.2%   
Net working cap to sales %19.3-15.1 -128.3%  
Current ratio x1.40.6 217.9%  
Inventory Days Days12431 395.6%  
Debtors Days Days10038 264.3%  
Net fixed assets Rs m1,689836,189 0.2%   
Share capital Rs m26238,647 0.7%   
"Free" reserves Rs m2,3580-   
Net worth Rs m2,6351,090,032 0.2%   
Long term debt Rs m507573,802 0.1%   
Total assets Rs m6,8623,732,269 0.2%  
Interest coverage x2.617.0 15.2%   
Debt to equity ratio x0.20.5 36.6%  
Sales to assets ratio x1.01.0 96.2%   
Return on assets %12.412.9 96.6%  
Return on equity %17.340.4 42.7%  
Return on capital %31.039.1 79.3%  
Exports to sales %4.00-   
Imports to sales %00-   
Net fx Rs m2710-   
CASH FLOW
From Operations Rs m-313442,609 -0.1%  
From Investments Rs m-489-27,229 1.8%  
From Financial Activity Rs m769-414,422 -0.2%  
Net Cashflow Rs m-33958 -3.4%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for UNILEVER PLC. (UK) is Euro. All data has been converted at 79.85 Rs / EUR

Compare AMAR REMEDIES With: P&G (US)  HYPERMARCAS (Brazil)  

Compare AMAR REMEDIES With: EMAMI LTD  MARICO LTD  KARUTURI GLOBAL  HIND. UNILEVER  LINC PEN & PLASTICS LTD  



Today's Market

Indian Indices Trade Strong; Metal, Pharma Stocks Lead Gains(01:30 pm)

After opening the day in green, share markets in India have continued the momentum and are presently trading above the dotted line.

Related Views On News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AMAR REMEDIES SHARE PRICE


Dec 11, 2013 (Close)

TRACK AMAR REMEDIES

  • Track your investment in AMAR REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AMAR REMEDIES 8-QTR ANALYSIS

COMPARE AMAR REMEDIES WITH

MARKET STATS